SCHEMBL6797432

SCHEMBL6797432

Cc1cccc(Sc2ccc(S(=O)(=O)N(CCN3CCOCC3)[C@@H](C(=O)O)C(C)C)cc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 8/20 0.56
MMP13 P45452 5/20 0.56
MMP9 P14780 7/20 0.41
MMP1 P03956 3/20 0.41
MMP14 P50281 3/20 0.41
TSHR P16473 1/20 0.39
MMP8 P22894 4/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MMP12 P39900 3/20 0.38
CASR P41180 2/20 0.38
BACE1 P56817 1/20 0.38
MMP3 P08254 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
BMP1 P13497 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6798645 0.92 MMP2 (0.61) MMP2MMP13MMP9MMP1MMP14
SCHEMBL6794521 0.91 MMP2 (0.56) MMP2MMP13MMP9MMP1MMP14
SCHEMBL6797057 0.91 MMP2 (0.67) MMP2MMP13MMP9MMP1MMP14
SCHEMBL6797054 0.91 MMP2 (0.67) MMP2MMP13MMP9MMP1MMP14
SCHEMBL8172369 0.85 MMP2 (0.56) MMP2MMP13MMP9MMP1MMP14
SCHEMBL6797086 0.83 MMP2 (0.49) MMP2MMP13MMP9TSHRMMP8
SCHEMBL6797087 0.83 MMP2 (0.49) MMP2MMP13MMP9TSHRMMP8
SCHEMBL6796505 0.82 MMP2 (0.52) MMP2MMP13TSHRCASRMMP3
SCHEMBL6794520 0.82 MMP2 (0.49) MMP2MMP13MMP9MMP1MMP14
SCHEMBL6800686 0.82 MMP2 (0.47) MMP2MMP13L3MBTL1MMP3USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0977745-B1 THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS PHARMACIA CORP (US) 2004-12-01 EP disclosed
US-20040034071-A1 Thioaryl sulfonamide hydroxamic acid compounds PHARMACIA CORPORATION 2004-02-19 US disclosed
US-6087359-A A MATRIX METALLOPROTEASE ENZYME INHIBITOR PHARMACIA CORPORATION 2000-07-11 US disclosed
EP-0977745-A1 THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 2000-02-09 EP disclosed
WO-1998039313-A1 THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 1998-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034071-A1 Thioaryl sulfonamide hydroxamic acid compounds MMP10, MMP1, MMP3 MMP2 4/4885MMP13 11/4885MMP9 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.